Metformin: The answer to cancer in a flower? current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer

Samson Mathews Samuel, Elizabeth Varghese, Peter Kubatka, Chris R. Triggle, Dietrich Büsselberg

Research output: Contribution to journalReview article

Abstract

Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incidence of breast cancer among diabetic individuals on a metformin treatment regimen, several in vitro, pre-clinical, and clinical studies reported the efficacy of using metformin individually as an anti-cancer/anti-tumor agent or in combination with chemotherapeutic drugs or radiation in the treatment of different forms of breast cancer. However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals. In the current article, we discuss the biology of metformin and its molecular mechanism of action, the existing cellular, pre-clinical, and clinical studies that have tested the anti-tumor potential of metformin as a potential anti-cancer/anti-tumor agent in breast cancer therapy, and outline the future prospects and directions for a better understanding and re-purposing of metformin as an anti-cancer drug in the treatment of breast cancer.

Original languageEnglish
Article number846
JournalBiomolecules
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 2019

Fingerprint

Metformin
Breast Neoplasms
Neoplasms
Tumors
Pharmaceutical Preparations
Radiation
Oncology
Medical problems
Therapeutics
Incidence
Cells
Meta-Analysis

Keywords

  • Anti-cancer therapy
  • Cancer
  • Combination therapy
  • Metformin
  • Natural compounds
  • Resistance

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Metformin : The answer to cancer in a flower? current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer. / Samuel, Samson Mathews; Varghese, Elizabeth; Kubatka, Peter; Triggle, Chris R.; Büsselberg, Dietrich.

In: Biomolecules, Vol. 9, No. 12, 846, 12.2019.

Research output: Contribution to journalReview article

@article{7b7dcd17bd9446a28241a1bd397fbaca,
title = "Metformin: The answer to cancer in a flower? current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer",
abstract = "Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incidence of breast cancer among diabetic individuals on a metformin treatment regimen, several in vitro, pre-clinical, and clinical studies reported the efficacy of using metformin individually as an anti-cancer/anti-tumor agent or in combination with chemotherapeutic drugs or radiation in the treatment of different forms of breast cancer. However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals. In the current article, we discuss the biology of metformin and its molecular mechanism of action, the existing cellular, pre-clinical, and clinical studies that have tested the anti-tumor potential of metformin as a potential anti-cancer/anti-tumor agent in breast cancer therapy, and outline the future prospects and directions for a better understanding and re-purposing of metformin as an anti-cancer drug in the treatment of breast cancer.",
keywords = "Anti-cancer therapy, Cancer, Combination therapy, Metformin, Natural compounds, Resistance",
author = "Samuel, {Samson Mathews} and Elizabeth Varghese and Peter Kubatka and Triggle, {Chris R.} and Dietrich B{\"u}sselberg",
year = "2019",
month = "12",
doi = "10.3390/biom9120846",
language = "English",
volume = "9",
journal = "Biomolecules",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Metformin

T2 - The answer to cancer in a flower? current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer

AU - Samuel, Samson Mathews

AU - Varghese, Elizabeth

AU - Kubatka, Peter

AU - Triggle, Chris R.

AU - Büsselberg, Dietrich

PY - 2019/12

Y1 - 2019/12

N2 - Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incidence of breast cancer among diabetic individuals on a metformin treatment regimen, several in vitro, pre-clinical, and clinical studies reported the efficacy of using metformin individually as an anti-cancer/anti-tumor agent or in combination with chemotherapeutic drugs or radiation in the treatment of different forms of breast cancer. However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals. In the current article, we discuss the biology of metformin and its molecular mechanism of action, the existing cellular, pre-clinical, and clinical studies that have tested the anti-tumor potential of metformin as a potential anti-cancer/anti-tumor agent in breast cancer therapy, and outline the future prospects and directions for a better understanding and re-purposing of metformin as an anti-cancer drug in the treatment of breast cancer.

AB - Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incidence of breast cancer among diabetic individuals on a metformin treatment regimen, several in vitro, pre-clinical, and clinical studies reported the efficacy of using metformin individually as an anti-cancer/anti-tumor agent or in combination with chemotherapeutic drugs or radiation in the treatment of different forms of breast cancer. However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals. In the current article, we discuss the biology of metformin and its molecular mechanism of action, the existing cellular, pre-clinical, and clinical studies that have tested the anti-tumor potential of metformin as a potential anti-cancer/anti-tumor agent in breast cancer therapy, and outline the future prospects and directions for a better understanding and re-purposing of metformin as an anti-cancer drug in the treatment of breast cancer.

KW - Anti-cancer therapy

KW - Cancer

KW - Combination therapy

KW - Metformin

KW - Natural compounds

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85076462523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076462523&partnerID=8YFLogxK

U2 - 10.3390/biom9120846

DO - 10.3390/biom9120846

M3 - Review article

C2 - 31835318

AN - SCOPUS:85076462523

VL - 9

JO - Biomolecules

JF - Biomolecules

SN - 2218-273X

IS - 12

M1 - 846

ER -